Serum Vaspin Concentration in Elderly Patients with Type 2 Diabetes Mellitus and Macrovascular Complications

Overview

Journal BMC Endocr Disord

Publisher Biomed Central

Specialty Endocrinology

Date 2017 Oct 26

PMID 29065866

Citations 7

Authors

Wei Yang

Yun Li

Tian Tian

Li Wang

Pearl Lee

Qi Hua

Affiliations

Soon will be listed here.

Abstract

Background: Adipose tissue, an endocrine organ of the body, is involved in some obesity-related disease states such as insulin resistance, diabetes mellitus, and atherosclerosis. Vaspin is a novel adipocyte with insulin sensitizing effects. In this study, we planned to estimate serum vaspin concentrations as related to glycemic status and the presence of macrovascular complications among elderly patients with type-2 diabetes mellitus (T2DM).

Methods: A total of 230 elderly patients with T2DM were evaluated. These patients were divided into two groups: patients without complications (T2DM group, n = 110), and patients with macrovascular complications (T2DM + MC group, n = 120). In addition, 60 healthy elderly subjects were enrolled and assigned into the control group (NC group). Relevant parameters were matched for age and gender ratio. Serum vaspin concentrations were measured by Enzyme-linked immunosorbent assay (ELISA). Anthropometric measurements, plasma glucose and HbA levels, insulin concentration, liver and kidney functions, and lipid profile were measured for each participant.

Results: Serum vaspin concentrations were significantly higher in the T2DM group than in the T2DM + MC group (F = 13.122, P < 0.01). These concentrations were also significantly higher among females, compared to males (T = 3.567, P < 0.05). Logistic regression analysis revealed that serum vaspin concentration, systolic blood pressure, HDL-C and T2DM duration were independent influencing factors for diabetic macrovascular complications.

Conclusion: Serum vaspin may be considered as a potential marker to assess the status of elderly patients with T2DM and the risk of developing serious macrovascular complications. Further prospective studies are warranted.

Trial Registration: ChiCTR-OPC-14005698 , retrospectively registered on 20 Dec. 2014.

Citing Articles

A Mediterranean Eating Pattern Combining Energy and Time-Restricted Eating Improves Vaspin and Omentin Concentrations Compared to Intermittent Fasting in Overweight Individuals.

Karras S, Koufakis T, Popovic D, Adamidou L, Karalazou P, Thisiadou K Nutrients. 2023; 15(24).

PMID: 38140318 PMC: 10745393. DOI: 10.3390/nu15245058.

Competing endogenous RNA network analysis explores the key lncRNAs, miRNAs, and mRNAs in type 1 diabetes.

Li C, Wei B, Zhao J BMC Med Genomics. 2021; 14(1):35.

PMID: 33526014 PMC: 7852109. DOI: 10.1186/s12920-021-00877-3.

Serum vaspin levels are positively associated with diabetic retinopathy in patients with type 2 diabetes mellitus.

Yang H, Huang Y, Gai C, Chai G, Lee S J Diabetes Investig. 2020; 12(4):566-573.

PMID: 32797727 PMC: 8015830. DOI: 10.1111/jdi.13385.

The Impact of Aging on Adipose Function and Adipokine Synthesis.

Mancuso P, Bouchard B Front Endocrinol (Lausanne). 2019; 10:137.

PMID: 30915034 PMC: 6421296. DOI: 10.3389/fendo.2019.00137.

Nesfatin-1 and Vaspin as Potential Novel Biomarkers for the Prediction and Early Diagnosis of Gestational Diabetes Mellitus.

Mierzynski R, Poniedzialek-Czajkowska E, Dluski D, Patro-Malysza J, Kimber-Trojnar Z, Majsterek M Int J Mol Sci. 2019; 20(1).

PMID: 30621139 PMC: 6337752. DOI: 10.3390/ijms20010159.

References

Jian W, Peng W, Xiao S, Li H, Jin J, Qin L . Role of serum vaspin in progression of type 2 diabetes: a 2-year cohort study. PLoS One. 2014; 9(4):e94763. PMC: 3986225. DOI: 10.1371/journal.pone.0094763. View

Fasshauer M, Bluher M . Adipokines in health and disease. Trends Pharmacol Sci. 2015; 36(7):461-70. DOI: 10.1016/j.tips.2015.04.014. View

Hida K, Poulsen P, Teshigawara S, Nilsson E, Friedrichsen M, Ribel-Madsen R . Impact of circulating vaspin levels on metabolic variables in elderly twins. Diabetologia. 2011; 55(2):530-2. DOI: 10.1007/s00125-011-2385-0. View

Gulcelik N, Karakaya J, Gedik A, Usman A, Gurlek A . Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol. 2008; 160(1):65-70. DOI: 10.1530/EJE-08-0723. View

Shah A, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale C . Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 2014; 3(2):105-13. PMC: 4303913. DOI: 10.1016/S2213-8587(14)70219-0. View

Kloting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schon M . Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun. 2005; 339(1):430-6. DOI: 10.1016/j.bbrc.2005.11.039. View

IDF Diabetes Atlas Group . Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2013. Diabetes Res Clin Pract. 2015; 109(3):461-5. DOI: 10.1016/j.diabres.2015.05.037. View

Chawla A, Chawla R, Jaggi S . Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?. Indian J Endocrinol Metab. 2016; 20(4):546-51. PMC: 4911847. DOI: 10.4103/2230-8210.183480. View

Seeger J, Ziegelmeier M, Bachmann A, Lossner U, Kratzsch J, Bluher M . Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab. 2007; 93(1):247-51. DOI: 10.1210/jc.2007-1853. View

10.

Wada J . [Vaspin and insulin resistance]. Rinsho Byori. 2008; 56(8):705-11. View

11.

Li H, Peng W, Cui S, Lei H, Wei Y, Li W . Vaspin plasma concentrations and mRNA expressions in patients with stable and unstable angina pectoris. Clin Chem Lab Med. 2011; 49(9):1547-54. DOI: 10.1515/CCLM.2011.236. View

12.

Villareal D, Chode S, Parimi N, Sinacore D, Hilton T, Armamento-Villareal R . Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011; 364(13):1218-29. PMC: 3114602. DOI: 10.1056/NEJMoa1008234. View

13.

Guthold R, Ono T, Strong K, Chatterji S, Morabia A . Worldwide variability in physical inactivity a 51-country survey. Am J Prev Med. 2008; 34(6):486-94. DOI: 10.1016/j.amepre.2008.02.013. View

14.

Xu Y, Wang L, He J, Bi Y, Li M, Wang T . Prevalence and control of diabetes in Chinese adults. JAMA. 2013; 310(9):948-59. DOI: 10.1001/jama.2013.168118. View

15.

Halter J, Musi N, Horne F, Crandall J, Goldberg A, Harkless L . Diabetes and cardiovascular disease in older adults: current status and future directions. Diabetes. 2014; 63(8):2578-89. PMC: 4113072. DOI: 10.2337/db14-0020. View

16.

Hao F, Zhang H, Zhu J, Kuang H, Yu Q, Bai M . Association between vaspin level and coronary artery disease in patients with type 2 diabetes. Diabetes Res Clin Pract. 2016; 113:26-32. DOI: 10.1016/j.diabres.2015.12.001. View

17.

Gerstein H, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N . Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368(9541):1096-105. DOI: 10.1016/S0140-6736(06)69420-8. View

18.

Youn B, Kloting N, Kratzsch J, Lee N, Park J, Song E . Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2007; 57(2):372-7. DOI: 10.2337/db07-1045. View

19.

Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A . Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005; 102(30):10610-5. PMC: 1180799. DOI: 10.1073/pnas.0504703102. View

20.

Stamler J, Vaccaro O, Neaton J, Wentworth D . Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16(2):434-44. DOI: 10.2337/diacare.16.2.434. View